JP2014502982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502982A5 JP2014502982A5 JP2013549780A JP2013549780A JP2014502982A5 JP 2014502982 A5 JP2014502982 A5 JP 2014502982A5 JP 2013549780 A JP2013549780 A JP 2013549780A JP 2013549780 A JP2013549780 A JP 2013549780A JP 2014502982 A5 JP2014502982 A5 JP 2014502982A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- dihydro
- oxazin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052736 halogen Inorganic materials 0.000 claims 29
- 150000002367 halogens Chemical class 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 14
- -1 cyano-C 1-6 -alkyl Chemical group 0.000 claims 13
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 12
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 238000011321 prophylaxis Methods 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 208000037259 Amyloid Plaque Diseases 0.000 claims 4
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 4
- 102100021277 Beta-secretase 2 Human genes 0.000 claims 4
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 4
- 101000894883 Homo sapiens Beta-secretase 2 Proteins 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 230000008021 deposition Effects 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000037765 diseases and disorders Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- SNBVGRNXFMZUNZ-INIZCTEOSA-N (5r)-5-[5-(cyclopentylamino)-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC2CCCC2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 SNBVGRNXFMZUNZ-INIZCTEOSA-N 0.000 claims 2
- BIQLWJAOBRCFDO-UHFFFAOYSA-N 5-[3-[(5-chloro-2,3-dihydro-1h-inden-1-yl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=CC(NC2C3=CC=C(Cl)C=C3CC2)=CC=1C1(C)COCC(N)=N1 BIQLWJAOBRCFDO-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- RWCZTUDBYGQJTK-LZWOXQAQSA-N (1r,2s)-2-[3-[(3r)-5-amino-3-methyl-2,6-dihydro-1,4-oxazin-3-yl]-4-fluoroanilino]cyclopentan-1-ol Chemical compound C=1C(N[C@@H]2[C@@H](CCC2)O)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 RWCZTUDBYGQJTK-LZWOXQAQSA-N 0.000 claims 1
- RWCZTUDBYGQJTK-DZKIICNBSA-N (1s,2s)-2-[3-[(3r)-5-amino-3-methyl-2,6-dihydro-1,4-oxazin-3-yl]-4-fluoroanilino]cyclopentan-1-ol Chemical compound C=1C(N[C@@H]2[C@H](CCC2)O)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 RWCZTUDBYGQJTK-DZKIICNBSA-N 0.000 claims 1
- QRXTWNWAFMAMIP-AWEZNQCLSA-N (5r)-5-[2-fluoro-5-(1,2-oxazol-3-ylamino)phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC2=NOC=C2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 QRXTWNWAFMAMIP-AWEZNQCLSA-N 0.000 claims 1
- FOMKAUKZKZNSRI-LBPRGKRZSA-N (5r)-5-[2-fluoro-5-(2,2,2-trifluoroethylamino)phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NCC(F)(F)F)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 FOMKAUKZKZNSRI-LBPRGKRZSA-N 0.000 claims 1
- IDIJEPWZHXCJCL-LBPRGKRZSA-N (5r)-5-[2-fluoro-5-(2,2,3,3,3-pentafluoropropylamino)phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NCC(F)(F)C(F)(F)F)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 IDIJEPWZHXCJCL-LBPRGKRZSA-N 0.000 claims 1
- YHBCCGYRJHZRIT-ZDUSSCGKSA-N (5r)-5-[2-fluoro-5-(3,3,3-trifluoropropylamino)phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NCCC(F)(F)F)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 YHBCCGYRJHZRIT-ZDUSSCGKSA-N 0.000 claims 1
- VEBDOPAMPGWBDV-NBFOKTCDSA-N (5r)-5-[2-fluoro-5-(3-methylbutan-2-ylamino)phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound CC(C)C(C)NC1=CC=C(F)C([C@@]2(C)N=C(N)COC2)=C1 VEBDOPAMPGWBDV-NBFOKTCDSA-N 0.000 claims 1
- VGSIYGKAKNKCHH-INIZCTEOSA-N (5r)-5-[2-fluoro-5-(3-methylbutylamino)phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound CC(C)CCNC1=CC=C(F)C([C@@]2(C)N=C(N)COC2)=C1 VGSIYGKAKNKCHH-INIZCTEOSA-N 0.000 claims 1
- HCGNKVLPKJMANG-HNNXBMFYSA-N (5r)-5-[2-fluoro-5-(3-methylsulfanylpropylamino)phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound CSCCCNC1=CC=C(F)C([C@@]2(C)N=C(N)COC2)=C1 HCGNKVLPKJMANG-HNNXBMFYSA-N 0.000 claims 1
- IUECETKEUARTFS-MHTVFEQDSA-N (5r)-5-[2-fluoro-5-(oxolan-3-ylamino)phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC2COCC2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 IUECETKEUARTFS-MHTVFEQDSA-N 0.000 claims 1
- FZNGSQOVFGNTTD-INIZCTEOSA-N (5r)-5-[2-fluoro-5-(pentan-3-ylamino)phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound CCC(CC)NC1=CC=C(F)C([C@@]2(C)N=C(N)COC2)=C1 FZNGSQOVFGNTTD-INIZCTEOSA-N 0.000 claims 1
- AZHQHJIUMFMAEH-SFHVURJKSA-N (5r)-5-[2-fluoro-5-[2-(2,2,2-trifluoroethoxy)anilino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC=2C(=CC=CC=2)OCC(F)(F)F)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 AZHQHJIUMFMAEH-SFHVURJKSA-N 0.000 claims 1
- CGDLCHMMXOYPSB-IBGZPJMESA-N (5r)-5-[2-fluoro-5-[2-(2-fluoroethoxy)anilino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC=2C(=CC=CC=2)OCCF)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 CGDLCHMMXOYPSB-IBGZPJMESA-N 0.000 claims 1
- PEKTURXUQVGPEG-NRFANRHFSA-N (5r)-5-[2-fluoro-5-[[3-(2,2,2-trifluoroethoxy)quinolin-8-yl]amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC=2C3=NC=C(OCC(F)(F)F)C=C3C=CC=2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 PEKTURXUQVGPEG-NRFANRHFSA-N 0.000 claims 1
- BAKRUGCZKCVDEM-QFIPXVFZSA-N (5r)-5-[2-fluoro-5-[[3-(2-fluoroethoxy)quinolin-8-yl]amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC=2C3=NC=C(OCCF)C=C3C=CC=2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 BAKRUGCZKCVDEM-QFIPXVFZSA-N 0.000 claims 1
- DSRMJUAEYUDBRT-ZDUSSCGKSA-N (5r)-5-[5-(2,2-difluoroethylamino)-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NCC(F)F)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 DSRMJUAEYUDBRT-ZDUSSCGKSA-N 0.000 claims 1
- FMVKCRWWNAQUEF-HNNXBMFYSA-N (5r)-5-[5-(butylamino)-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound CCCCNC1=CC=C(F)C([C@@]2(C)N=C(N)COC2)=C1 FMVKCRWWNAQUEF-HNNXBMFYSA-N 0.000 claims 1
- KKLMFSIUUFHDAW-HNNXBMFYSA-N (5r)-5-[5-(cyclobutylamino)-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC2CCC2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 KKLMFSIUUFHDAW-HNNXBMFYSA-N 0.000 claims 1
- MFIGRCBCTKHMRZ-KRWDZBQOSA-N (5r)-5-[5-(cyclohexylamino)-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC2CCCCC2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 MFIGRCBCTKHMRZ-KRWDZBQOSA-N 0.000 claims 1
- ORNNHNZPHILLPY-HNNXBMFYSA-N (5r)-5-[5-(cyclopropylmethylamino)-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NCC2CC2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 ORNNHNZPHILLPY-HNNXBMFYSA-N 0.000 claims 1
- QMXOUBXMBUQGFI-FQEVSTJZSA-N (5r)-5-[5-[(3-chloro-6-fluoroquinolin-8-yl)amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC=2C3=NC=C(Cl)C=C3C=C(F)C=2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 QMXOUBXMBUQGFI-FQEVSTJZSA-N 0.000 claims 1
- UCGIYSHWKADWCV-BDQAORGHSA-N (5r)-5-[5-[(3-chloro-6-fluoroquinolin-8-yl)amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine;hydrochloride Chemical compound Cl.C=1C(NC=2C3=NC=C(Cl)C=C3C=C(F)C=2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 UCGIYSHWKADWCV-BDQAORGHSA-N 0.000 claims 1
- QIANIVYIOVZEHV-FQEVSTJZSA-N (5r)-5-[5-[(3-chloroquinolin-8-yl)amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC=2C3=NC=C(Cl)C=C3C=CC=2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 QIANIVYIOVZEHV-FQEVSTJZSA-N 0.000 claims 1
- OSRJQZXSYLZQHL-BDQAORGHSA-N (5r)-5-[5-[(3-chloroquinolin-8-yl)amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine;hydrochloride Chemical compound Cl.C=1C(NC=2C3=NC=C(Cl)C=C3C=CC=2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 OSRJQZXSYLZQHL-BDQAORGHSA-N 0.000 claims 1
- QNHDYGNNUMCCRR-IBGZPJMESA-N (5r)-5-[5-[2-(2,2-difluoroethoxy)anilino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC=2C(=CC=CC=2)OCC(F)F)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 QNHDYGNNUMCCRR-IBGZPJMESA-N 0.000 claims 1
- RUMTVFXUGDDVFV-FYZYNONXSA-N (5r)-5-[5-[2-(2,2-difluoroethoxy)anilino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine;hydrochloride Chemical compound Cl.C=1C(NC=2C(=CC=CC=2)OCC(F)F)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 RUMTVFXUGDDVFV-FYZYNONXSA-N 0.000 claims 1
- XUDAQSPLHDYMTP-ANYOKISRSA-N (5r)-5-[5-[[1-(5-chloropyridin-2-yl)-2-methylpropyl]amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=C(Cl)C=NC=1C(C(C)C)NC(C=1)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 XUDAQSPLHDYMTP-ANYOKISRSA-N 0.000 claims 1
- HLTYVBBHDLMJQB-DEOSSOPVSA-N (5r)-5-[5-[[3-(cyclopropylmethoxy)-6-fluoroquinolin-8-yl]amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC=2C3=NC=C(OCC4CC4)C=C3C=C(F)C=2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 HLTYVBBHDLMJQB-DEOSSOPVSA-N 0.000 claims 1
- CHPYWNCYTLASBD-NRFANRHFSA-N (5r)-5-[5-[[3-(difluoromethoxy)quinolin-8-yl]amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC=2C3=NC=C(OC(F)F)C=C3C=CC=2)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 CHPYWNCYTLASBD-NRFANRHFSA-N 0.000 claims 1
- UWJFBDWADBANMX-INIZCTEOSA-N (5r)-5-[5-[[4-chloro-1-(difluoromethyl)pyrazol-3-yl]methylamino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NCC=2C(=CN(N=2)C(F)F)Cl)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 UWJFBDWADBANMX-INIZCTEOSA-N 0.000 claims 1
- KAOAHIXEJPGZSC-NTISSMGPSA-N (5r)-5-[5-[[4-chloro-1-(difluoromethyl)pyrazol-3-yl]methylamino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine;hydrochloride Chemical compound Cl.C=1C(NCC=2C(=CN(N=2)C(F)F)Cl)=CC=C(F)C=1[C@]1(C)COCC(N)=N1 KAOAHIXEJPGZSC-NTISSMGPSA-N 0.000 claims 1
- IVCFPJIINVIDFL-ROPPNANJSA-N (5s)-5-[5-[(5-chloro-2,3-dihydro-1h-inden-1-yl)amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C(NC2C3=CC=C(Cl)C=C3CC2)=CC=C(F)C=1[C@@]1(C)COCC(N)=N1 IVCFPJIINVIDFL-ROPPNANJSA-N 0.000 claims 1
- JXUFFJSEYVIGAA-MLVYHOMMSA-N (5s)-5-[5-[(5-chloro-2,3-dihydro-1h-inden-1-yl)amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine;hydrochloride Chemical compound Cl.C=1C(NC2C3=CC=C(Cl)C=C3CC2)=CC=C(F)C=1[C@@]1(C)COCC(N)=N1 JXUFFJSEYVIGAA-MLVYHOMMSA-N 0.000 claims 1
- TWQFDPFLUOXDSO-LJQANCHMSA-N (5s)-5-[5-[(6-chloro-1-methylindazol-3-yl)amino]-2-fluorophenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C12=CC=C(Cl)C=C2N(C)N=C1NC(C=1)=CC=C(F)C=1[C@@]1(C)COCC(N)=N1 TWQFDPFLUOXDSO-LJQANCHMSA-N 0.000 claims 1
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- MCRHAPLPANRVQW-UHFFFAOYSA-N 5-[3-[(1,2-dimethylbenzimidazol-5-yl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=C2N(C)C(C)=NC2=CC=1NC(C=1)=CC=CC=1C1(C)COCC(N)=N1 MCRHAPLPANRVQW-UHFFFAOYSA-N 0.000 claims 1
- XIAJXBYPLFZIKS-UHFFFAOYSA-N 5-[3-[(2,4-dichlorophenyl)methylamino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=CC(NCC=2C(=CC(Cl)=CC=2)Cl)=CC=1C1(C)COCC(N)=N1 XIAJXBYPLFZIKS-UHFFFAOYSA-N 0.000 claims 1
- MNPQSOIYEJRNIW-UHFFFAOYSA-N 5-[3-[(3-chlorophenyl)methylamino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=CC(NCC=2C=C(Cl)C=CC=2)=CC=1C1(C)COCC(N)=N1 MNPQSOIYEJRNIW-UHFFFAOYSA-N 0.000 claims 1
- MISZEAYFRRVHET-UHFFFAOYSA-N 5-[3-[(3-chloroquinolin-8-yl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=CC(NC=2C3=NC=C(Cl)C=C3C=CC=2)=CC=1C1(C)COCC(N)=N1 MISZEAYFRRVHET-UHFFFAOYSA-N 0.000 claims 1
- MADKDOVWBWXDFY-UHFFFAOYSA-N 5-[3-[(3-chloroquinolin-8-yl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine;hydrochloride Chemical compound Cl.C=1C=CC(NC=2C3=NC=C(Cl)C=C3C=CC=2)=CC=1C1(C)COCC(N)=N1 MADKDOVWBWXDFY-UHFFFAOYSA-N 0.000 claims 1
- IGUZINVHWNCBIH-UHFFFAOYSA-N 5-[3-[(3-methoxyquinolin-8-yl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=CC2=CC(OC)=CN=C2C=1NC(C=1)=CC=CC=1C1(C)COCC(N)=N1 IGUZINVHWNCBIH-UHFFFAOYSA-N 0.000 claims 1
- SCTBKUXFMWEWHM-UHFFFAOYSA-N 5-[3-[(3-methoxyquinolin-8-yl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine;hydrochloride Chemical compound Cl.C=1C=CC2=CC(OC)=CN=C2C=1NC(C=1)=CC=CC=1C1(C)COCC(N)=N1 SCTBKUXFMWEWHM-UHFFFAOYSA-N 0.000 claims 1
- AMUVGZZEIPOFNT-UHFFFAOYSA-N 5-[3-[(4-chlorophenyl)methylamino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=CC(NCC=2C=CC(Cl)=CC=2)=CC=1C1(C)COCC(N)=N1 AMUVGZZEIPOFNT-UHFFFAOYSA-N 0.000 claims 1
- HVJWQSJYUBCYNJ-UHFFFAOYSA-N 5-[3-[1-(4-chlorophenyl)ethylamino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=C(Cl)C=CC=1C(C)NC(C=1)=CC=CC=1C1(C)COCC(N)=N1 HVJWQSJYUBCYNJ-UHFFFAOYSA-N 0.000 claims 1
- IIOABHPKSLIUSW-UHFFFAOYSA-N 5-[3-[2-(difluoromethoxy)anilino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=CC(NC=2C(=CC=CC=2)OC(F)F)=CC=1C1(C)COCC(N)=N1 IIOABHPKSLIUSW-UHFFFAOYSA-N 0.000 claims 1
- SLVBZOAXQUILQV-UHFFFAOYSA-N 5-methyl-5-[3-(quinolin-8-ylamino)phenyl]-2,6-dihydro-1,4-oxazin-3-amine Chemical compound C=1C=CC(NC=2C3=NC=CC=C3C=CC=2)=CC=1C1(C)COCC(N)=N1 SLVBZOAXQUILQV-UHFFFAOYSA-N 0.000 claims 1
- 208000012181 Alzheimer disease 13 Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 102000007368 Ataxin-7 Human genes 0.000 claims 1
- 108010032953 Ataxin-7 Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000025212 Constitutional neutropenia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010016228 Fasciitis Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 208000027207 Whipple disease Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- QPTMIQYCEQIDKW-UHFFFAOYSA-N n-[3-(5-amino-3-methyl-2,6-dihydro-1,4-oxazin-3-yl)phenyl]-2-cyclopropyl-1,3-benzoxazol-4-amine Chemical compound C=1C=CC(NC=2C=3N=C(OC=3C=CC=2)C2CC2)=CC=1C1(C)COCC(N)=N1 QPTMIQYCEQIDKW-UHFFFAOYSA-N 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000027390 severe congenital neutropenia 3 Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11151294.3 | 2011-01-18 | ||
| EP11151294 | 2011-01-18 | ||
| PCT/EP2012/050537 WO2012098064A1 (en) | 2011-01-18 | 2012-01-16 | 1,4 oxazines as bace1 and/or bace2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014502982A JP2014502982A (ja) | 2014-02-06 |
| JP2014502982A5 true JP2014502982A5 (https=) | 2015-03-05 |
Family
ID=45491607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549780A Pending JP2014502982A (ja) | 2011-01-18 | 2012-01-16 | Ｂａｃｅ１及び／又はｂａｓｅ２阻害剤としての１，４オキサジン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9242943B2 (https=) |
| EP (1) | EP2665713A1 (https=) |
| JP (1) | JP2014502982A (https=) |
| KR (1) | KR20140014133A (https=) |
| CN (1) | CN103328454A (https=) |
| BR (1) | BR112013016360A2 (https=) |
| CA (1) | CA2819158A1 (https=) |
| MX (1) | MX2013007558A (https=) |
| RU (1) | RU2013135678A (https=) |
| WO (1) | WO2012098064A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2628074C (en) | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
| US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
| JP5383484B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | 環式基で置換されたアミノジヒドロチアジン誘導体 |
| KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| MX2012006491A (es) | 2009-12-11 | 2012-07-03 | Shionogi & Co | Derivados de oxazina. |
| MX339640B (es) | 2010-06-09 | 2016-06-01 | Janssen Pharmaceutica Nv * | Derivados de 5, 6-dihidro-2h-[1, 4] oxazin-3-il-amina utiles como inhibidores de la beta-secretasa (bace). |
| JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
| EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| EP2655376B1 (en) | 2010-12-22 | 2017-08-23 | Janssen Pharmaceutica NV | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
| CN103415519B (zh) | 2011-03-01 | 2016-03-02 | 詹森药业有限公司 | 作为β-分泌酶(BACE)抑制剂有用的6，7-二氢-吡唑[1，5-a]吡嗪-4-基胺衍生物 |
| AU2012224632B2 (en) | 2011-03-09 | 2016-06-16 | Janssen Pharmaceutica Nv | 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2694521B1 (en) | 2011-04-07 | 2015-11-25 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| CN103874496A (zh) | 2011-08-22 | 2014-06-18 | 默沙东公司 | 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途 |
| US9284284B2 (en) | 2011-10-13 | 2016-03-15 | Novartis Ag | Oxazine derivatives and their use in the treatment of disease |
| EP2788335B1 (en) * | 2011-12-06 | 2016-04-13 | Janssen Pharmaceutica, N.V. | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives for the treatment of disorders in which beta-secretase is involved |
| WO2014059185A1 (en) * | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| MX368326B (es) | 2013-06-12 | 2019-09-27 | Janssen Pharmaceutica Nv | Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace). |
| KR102243134B1 (ko) | 2013-06-12 | 2021-04-22 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체 |
| BR112015030597A2 (pt) | 2013-06-12 | 2017-07-25 | Janssen Pharmaceutica Nv | derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace) |
| ES2768823T3 (es) | 2014-12-18 | 2020-06-23 | Janssen Pharmaceutica Nv | Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa |
| EP3271355B1 (en) | 2015-03-20 | 2020-07-29 | H. Hoffnabb-La Roche Ag | Bace1 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SV2006002232A (es) | 2004-09-21 | 2006-05-25 | Lilly Co Eli | Inhibidores bace ref. x-16940 |
| WO2009024615A1 (en) * | 2007-08-23 | 2009-02-26 | Novartis Ag | Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors |
| KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| UY32799A (es) * | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| US8673894B2 (en) * | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| US8748418B2 (en) * | 2011-03-18 | 2014-06-10 | Hoffmann-La Roche Inc. | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors |
| US8785436B2 (en) * | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
-
2012
- 2012-01-12 US US13/348,675 patent/US9242943B2/en not_active Expired - Fee Related
- 2012-01-16 BR BR112013016360A patent/BR112013016360A2/pt not_active IP Right Cessation
- 2012-01-16 CN CN201280005579XA patent/CN103328454A/zh active Pending
- 2012-01-16 CA CA2819158A patent/CA2819158A1/en not_active Abandoned
- 2012-01-16 JP JP2013549780A patent/JP2014502982A/ja active Pending
- 2012-01-16 MX MX2013007558A patent/MX2013007558A/es active IP Right Grant
- 2012-01-16 WO PCT/EP2012/050537 patent/WO2012098064A1/en not_active Ceased
- 2012-01-16 RU RU2013135678/04A patent/RU2013135678A/ru not_active Application Discontinuation
- 2012-01-16 KR KR1020137021420A patent/KR20140014133A/ko not_active Withdrawn
- 2012-01-16 EP EP12700341.6A patent/EP2665713A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502982A5 (https=) | ||
| RU2013135678A (ru) | 1,4 оксазины в качестве ингибиторов васе1 и(или) васе2 | |
| JP7556010B2 (ja) | ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 | |
| JP7555327B2 (ja) | Ｎｌｒｐ３インフラマソーム阻害剤 | |
| US7999006B2 (en) | Methods of using MEK inhibitors | |
| JP2014528433A5 (https=) | ||
| JP2024540445A5 (https=) | ||
| JP6595078B2 (ja) | アミノカルボニルカルバメート化合物 | |
| RU2012148818A (ru) | 2,5,6,7-тетрагидро-[1,4]оксазепин-3-илмаины или 2,3,6,7-тетрагидро-[1,4]оксазепин-5-иламины | |
| JP2014507455A5 (https=) | ||
| JP2008526888A5 (https=) | ||
| RU2016110483A (ru) | Производные пирролопиридина или пиразолопиридина | |
| RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| US20230192676A1 (en) | Heterocyclic Amides as Kinase Inhibitors | |
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| RU2014101464A (ru) | Циклопропил-конденсированные-1,3-тиазепины в качестве ингибиторов васе 1 и(или) васе 2 | |
| JP2017509676A5 (https=) | ||
| MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
| JP2016525142A5 (https=) | ||
| JP2019529460A5 (https=) | ||
| JP2015502371A5 (https=) | ||
| JP2013525490A5 (https=) | ||
| WO2023091554A9 (en) | Novel heteroaryl-urea compounds as kv7.2 inhibitors | |
| JP2015536965A5 (https=) |